STEMI - ST Elevation Myocardial Infarction
Conditions
Keywords
anticoagulantion, post-procedure, STEMI
Brief summary
The RIGHT study is a large randomized study dedicated to post-PPCI anticoagulation in STEMI patients. The investigators propose to evaluate the clinical efficacy and safety of anticoagulation prolonged for at least 48 hours after the procedure vs. no prolongation of anticoagulation after procedure in patients with STEMI treated with bivalirudin during PPCI (primary hypothesis). When allocated to anticoagulation prolongation by randomization, the subject will be assigned to UFH, enoxaparin or bivalirudin (same regimen allocated by centre) for at least 48 hours after PPCI. The results from this study are expected to provide guidance on the risk/benefit of post-procedural anticoagulation in patients with STEMI.
Detailed description
A minor change of time of randomization after prolongation of bivalirudin infusion at PCI dose up to 4 hours on protocol at September 19,2018. Reasons: a minor change concerning the timing of randomization considering the current local practice in some centers that use the 4 hour infusion of bivalirudin just after PCI. It remains in agreement with the current international guidelines and with the drug label in China. There is no change in drugs used and doses of these drugs once the randomization occurs.
Interventions
DRUGBivalirudin
IV infusion of 0.2 mg/kg/h (low-rate infusion) for at least 48h after the procedure or until discharge from CCU if it occurs later
DRUGEnoxaparin
40mg/d s.c.for at least 48h after the procedure or until discharge from CCU if it occurs later
DRUGUnfractionated heparin
IV infusion of 10 U/kg/h (maximum 1000 U) initially, adjusted to maintain ACT between 150 and 220 seconds for at least 48h after the procedure or until discharge from CCU if it occurs later
DRUGBivalirudin placebo
Matching placebo IV infusion for at least 48h after the procedure or until discharge from CCU if it occurs later
DRUGEnoxaparin placebo syringe
Placebo syringe will be only prepared by a designated unblended medical professional on site. Placebo syringe will be presented in identical containers as a clear, colorless, sterile liquid of saline.Subcutaneous injection once a day for at least 48 hours after the procedure or until discharge from CCU if it occurs later.
DRUGUnfractionated heparin placebo
Matching placebo IV infusion for at least 48h after the procedure or until discharge from CCU if it occurs later.
Sponsors
Chinese Academy of Medical Sciences, Fuwai Hospital
ACTION Study Group (Pitié-Salpêtrière Hospital), Paris, France
Beijing Anzhen Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥18 years old * STEMI with PPCI of culprit lesion * Bivalirudin therapy during PPCI * Signed informed consent form
Exclusion criteria
* Patients with a formal indication for anticoagulation after PPCI (e.g. atrial fibrillation, left-ventricular thrombus, intra-aortic balloon pump, pulmonary embolism, mechanical heart valve) * Patients with any indication for chronic anticoagulation * Patient with previous lytic treatment * Patient with previous coronary artery bypass graft surgery * Cardiogenic shock, malignant ventricular arrhythmia, or mechanical complications * Any anticoagulation other than bivalirudin started after the procedure before randomization * Estimated body weight of \>120 kg or \<45kg * BP ≥180/110mmHg at randomization * Any bleeding diathesis or severe hematologic disease or history of intracerebral mass, aneurysm, arteriovenous malformation, recent (\<6months) ischemic stroke or TIA, recent (\<6months) intracranial hemorrhage or, gastrointestinal or genitourinary bleeding within the past 2 weeks * History of heparin-induced thrombocytopenia * Suspected acute aortic dissection (AAD) * Major surgery within 1 month * A planned elective surgical procedure that would necessitate an interruption in treatment with P2Y12 inhibitors in the next 6 months after enrollment * Known PLT≤100×109 or HGB≤10g/L * Known transaminase \>3-fold ULN, or CCr\<30ml/min * Known allergy to any study drug * Pregnancy or lactation * Noncardiac coexisting conditions that could limit life expectancy to less than 1 year * Current participation in an investigational drug or device trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Primary efficacy endpoint - number of event of a composite of all-cause death, non-fatal myocardial infarction, non-fatal stroke, stent thrombosis (definite) or urgent revascularization (any vessel) | 30 days | The number of event of a composite of all-cause death, non-fatal myocardial infarction, non-fatal stroke, stent thrombosis (definite) or urgent revascularization (any vessel) within 30 days after randomization |
| Primary safety endpoint - The number of event of major bleeding | 30 days | The number of event of major bleeding (BARC 3 to 5) within 30 days after randomization |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Secondary ischemic endpoints - The number of event of a composite of all-cause death, non-fatal myocardial infarction, or non-fatal stroke | 30 days | The number of event of a composite of all-cause death, non-fatal myocardial infarction, or non-fatal stroke within 30 days after randomization |
| Secondary ischemic endpoints - The number of event of a composite of all-cause death or non-fatal myocardial infarction | 30 days | The number of event of a composite of all-cause death or non-fatal myocardial infarction within 30 days after randomization |
| Secondary ischemic endpoints - The number of cardiovascular death events | 30 days | The number of cardiovascular death event within 30 days after randomization |
| Secondary ischemic endpoints - The number of stent thrombosis (ARC definite) events | 30 days | The number of stent thrombosis (ARC definite) event within 30 days after randomization |
| Secondary safety endpoints - The number of bleeding events (TIMI, STEEPLE and GUSTO definition) | 30 days | The number of bleeding events (TIMI, STEEPLE and GUSTO definition) within 30 days after randomization To demonstrate that post-procedure anticoagulation with UFH, enoxaparin or bivalirudin as compared to their placebo is associated to lower rate of the composite endpoint of major bleeding according to TIMI, STEEPLE and GUSTO definitions within the first 30 days after randomization. |
| Secondary safety endpoints - The number of thrombocytopenia events | 30 days | The number of thrombocytopenia events within 30 days after randomization To demonstrate superiority of a strategy of post-procedure anticoagulation with UFH, enoxaparin or bivalirudin as compared to their placebo by the time from randomization to the first occurrence of any event of the Thrombocytopenia endpoint over 30 days of follow-up. |
Countries
China
Outcome results
None listed